• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Schrodinger Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/23/26 4:10:58 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    sdgr-20260622
    1540 Broadway24th FloorNew YorkNYFALSE000149097800014909782026-06-222026-06-22

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ________________________________________
    FORM 8-K
    ________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 22, 2026
    ________________________________________
    Schrodinger, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    ________________________________________
    Delaware001-3920695-4284541
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    (Commission File Number)
    1540 Broadway, 24th Floor
    New York, NY
    10036
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (212) 295-5800
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    ________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of each exchange on which registered
    Common stock, par value $0.01 per shareSDGRThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

    Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    At the 2026 Annual Meeting of Stockholders of Schrödinger, Inc. (the “Company”) held on June 22, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2026 Plan Amendment”) to the Schrödinger, Inc. 2022 Equity Incentive Plan, as amended (the “2022 Equity Incentive Plan”). The 2026 Plan Amendment, which had previously been adopted by the Company’s Board of Directors (the “Board”) subject to stockholder approval, increases the number of shares of common stock of the Company available for issuance under the 2022 Equity Incentive Plan by 3,000,000 shares.
    The description of the 2022 Equity Incentive Plan, as amended by the 2026 Plan Amendment, contained on pages 18 to 29 of the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2026 (the “Proxy Statement”), is incorporated herein by reference. A complete copy of the 2022 Equity Incentive Plan, as amended by the 2026 Plan Amendment, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
    Item 5.07.    Submission of Matters to a Vote of Security Holders.
    At the Annual Meeting, the Company’s stockholders voted on the four proposals set forth below. A more detailed description of each proposal is set forth in the Proxy Statement.
    Holders of the Company’s common stock were entitled to one vote per share of common stock on each matter brought before the Annual Meeting. Holders of the Company’s limited common stock were entitled to one vote per share of limited common stock on each matter brought before the Annual Meeting, except that each share of limited common stock was not entitled to vote on the election of directors.
    Proposal 1 – Election of Three Class III Directors
    The Company’s stockholders elected Richard A. Friesner, Rosana Kapeller-Libermann and Gary Sender as Class III directors of the Board, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class III directors were as follows:
    NomineeNumber of Shares of Common Stock FORNumber of Shares of Common Stock AGAINSTNumber of Shares of Common Stock ABSTAININGBROKER NON-VOTES
    Richard A. Friesner33,634,8799,424,52568,3399,593,955
    Rosana Kapeller-Libermann32,336,27310,723,56567,9059,593,955
    Gary Sender33,506,4869,552,23569,0229,593,955
    Proposal 2 – Advisory Vote on Executive Compensation
    The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:



    Number of Shares FORNumber of Shares AGAINSTNumber of Shares ABSTAININGBROKER NON-VOTES
    Common Stock42,181,182870,92675,6359,593,955
    Limited Common Stock9,164,193000
    Total51,345,375870,92675,6359,593,955
    Proposal 3 – Approval of an Amendment to the 2022 Equity Incentive Plan to Increase the Number of Shares of the Company’s Common Stock Available for Issuance Thereunder by 3,000,000 Shares
    The Company’s stockholders approved the 2026 Plan Amendment. The results of the stockholders’ vote with respect to the 2026 Plan Amendment were as follows:
    Number of Shares FORNumber of Shares AGAINSTNumber of Shares ABSTAININGBROKER NON-VOTES
    Common Stock32,257,90310,825,54744,2939,593,955
    Limited Common Stock9,164,193000
    Total41,422,09610,825,54744,2939,593,955
    Proposal 4 – Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026
    The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:
    Number of Shares FORNumber of Shares AGAINSTNumber of Shares ABSTAINING
    Common Stock52,509,921179,55932,218
    Limited Common Stock9,164,19300
    Total61,674,114179,55932,218
    Item 9.01.     Financial Statements and Exhibits.
    (d) Exhibits:

    Exhibit
    Number
    Description
    99.1
    Schrödinger, Inc. 2022 Equity Incentive Plan, as amended (incorporated by reference to Appendix B to the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-39206) filed with the SEC on April 28, 2026)
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    Schrödinger, Inc.
    Date: June 23, 2026By:/s/ Yvonne Tran
    Yvonne Tran
    Chief Legal Officer and Corporate Secretary








    Get the next $SDGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    9/30/2025$19.00Neutral
    Goldman
    8/15/2025$20.00Buy → Neutral
    Citigroup
    8/14/2025$25.00Overweight
    Barclays
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    More analyst ratings

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Schrödinger, Inc. (NASDAQ:SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs v

    6/18/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Schrödinger, Inc. (NASDAQ:SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635

    5/22/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Schrodinger upgraded by BofA Securities with a new price target

    BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00

    12/15/25 9:09:21 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Schrodinger with a new price target

    Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00

    9/30/25 8:57:53 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger downgraded by Citigroup with a new price target

    Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00

    8/15/25 8:18:12 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    SEC Filings

    View All

    Schrodinger Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    6/23/26 4:10:58 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    6/8/26 4:22:56 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    5/20/26 4:19:47 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Oberoi Arun was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/23/26 5:01:15 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chodakewitz Jeffrey was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/23/26 4:38:47 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Friesner Richard was granted 8,141 shares, increasing direct ownership by 1% to 690,365 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/23/26 4:38:26 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Financials

    Live finance-specific insights

    View All

    Schrödinger Reports First Quarter 2026 Financial Results

    First Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer Lilly's Announced $2.3 Billion Acquisition of Ajax Validates Schrödinger's Track Record of High-Value Collaborations Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2026. "Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth of 12 percent was driven by usage scale-ups and new deployments; we are also pleased with our progress transitioning customers to hosted licensing. The biopharmaceutical funding env

    5/5/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce First Quarter 2026 Financial Results on May 5

    Schrödinger, Inc. (NASDAQ:SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharma

    4/21/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Schrodinger Inc.

    SC 13G - Schrodinger, Inc. (0001490978) (Subject)

    11/13/24 4:30:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    2/13/24 5:13:59 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    1/23/24 11:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

    5/29/25 8:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

    3/10/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care